Medical/Pharmaceuticals
China Marches into the Era of Interventional Direct Annuloplasty
Launching of the 1st Human Implantation of "DragonRing" – Catheter-based Mitral Annuloplasty Device HANGZHOU, China, Nov. 5, 2022 /PRNewswire/ -- On October 28, 2022, a multidisciplinary, and international cardiac team led by ProfessorMao Chen from Department of Cardiology, West China Hospital,S...
2022-11-06 01:44
2654
Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
* Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data * The research demonstrated that treatment with FT011 results in a remarkable...
2022-11-04 20:00
2391
Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC
HONG KONG, Nov. 3, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab (PD-1/VEGF bi-specific antibody, AK112) combined with chemotherapy for the treatment of EGFR-mutant locally advanced or metasta...
2022-11-04 08:57
1613
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the initial results from a global Phase II st...
2022-11-04 03:33
2527
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results from three studies of ...
2022-11-04 03:32
1967
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharm...
2022-11-03 21:10
2019
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and ...
2022-11-03 21:01
2275
Yuyu Pharma attendance at European Pharmaceutical Conference
SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma,
has been attending biopharmaceutical conferences held inGermany, BIO-Europe and
CPHI. The purpose is to explore opportunities to expand into international
markets, such as Europe.
2022-11-03 21:00
2105
Zhongchao Inc.'s China Operating Entity, Chongqing Xinjiang Pharmaceutical Co., Ltd. Obtained Pharmaceutical Trade and Medical Device Operation Licenses, Ready to Enter Into Pharmaceuticals Circulation Market
SHANGHAI, Nov. 3, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that one of theChina operating entities of which the Company cons...
2022-11-03 19:30
1821
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...
2022-11-03 19:00
1545
Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004
BOSTON and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mell...
2022-11-03 13:11
1944
Shanghai Operation Robot announced the first Robot-assisted human clinical trial of biliary stent placement surgery
SHANGHAI, Nov. 2, 2022 /PRNewswire/ -- Shanghai Operation Robot Co.,Ltd announced the results of its initial clinical trial of ERCP (Endoscopic retrograde cholangiopancreatography) robot in biliary stent placement surgery. It is the first Robot-assisted human clinical trial of biliary stent place...
2022-11-02 13:55
1652
WAT Medical Entrusted By Geely Auto To Develop Neuromodulation Technologies To Improve Travel Experiences
VANCOUVER, BC, Nov. 1, 2022 /PRNewswire/ -- With the foreseeable increase in outdoor travelling in the near future, as well as the ever-expanding prospects of self-driving vehicles that have been reported to increase the incidence of nausea and vomiting, motion sickness is becoming a continuously...
2022-11-02 01:15
2183
Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)
* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...
2022-11-01 22:00
2321
New Randomized Controlled Study Published in JAMA Demonstrates the Value of Clinical Decision Support Tools in Preventing Acute Kidney Injury in Patients Undergoing Coronary Angiography
– Researchers used Terumo Health Outcomes' ePRISM® software to calculate safe
contrast volume targets and improve overall patient outcomes –
SOMERSET, N.J., Nov. 1, 2022 /PRNewswire/ -- A new study published in JAMA
2022-11-01 20:00
1471
CBC Healthcare Infrastructure Platform acquires prime industrial land in Shanghai to develop a high-specifications life science park
* 83.76 mu plot within the Life Science zone of the Qingpu Industrial Park, Shanghai Development to include manufacturing facilities and R&D offices SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CBC Healthcare Infrastructure Platform ("CBC HIP"), the infrastructure arm ofAsia's largest healthcare-de...
2022-11-01 11:00
1871
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs
SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior V...
2022-10-31 21:30
2714
Announcement of the Effect of Ginseng and Red Ginseng for Memory Improvement and Suppression of Bone and Muscle Loss
* Effect of improving blood pressure in patients with high blood pressure and diabetes * Announced at the 13th International Symposium on Ginseng 2022 SEOUL, South Korea, Oct. 31, 2022 /PRNewswire/ -- Experts who have conducted scientific studies on the effect of ginseng gathered inSeoul from...
2022-10-31 21:08
3164
Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2022-10-31 21:00
2207
Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer
TAIPEI and SAN DIEGO, Oct. 31, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been successfully dosed, in a phase I c...
2022-10-31 19:00
2490
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8873
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7709